Abstract
This report describes a safe and effective therapy through adoptive transfer of donor cytomegalovirus (CMV)/Epstein-Barr virus (EBV) immune effector cells. The patients, from 3 to 10 years of age, suffering from hematologic diseases received haploidentical transplantation. All 3 patients developed varying levels of viremia from days 13 to 31 and 2 patients developed CMV-interstitial pneumonitis or interstitial inflammation after transplantation. Tapering down the dose of immunosuppressives together with intensive antivirus therapy and escalated infusions of donor-derived CMV/EBV immune effector cells effectively controlled virus-related diseases. All 3 patients survived and remained CMV/EBV-free 14-16 months after transplantation.
Publication types
-
Case Reports
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adoptive Transfer / methods*
-
Child
-
Child, Preschool
-
Cytomegalovirus / immunology*
-
Cytomegalovirus Infections / etiology
-
Cytomegalovirus Infections / prevention & control
-
Dendritic Cells / transplantation
-
Dendritic Cells / virology
-
Epstein-Barr Virus Infections / etiology
-
Epstein-Barr Virus Infections / prevention & control
-
Female
-
Hematologic Neoplasms / complications
-
Hematologic Neoplasms / therapy
-
Hematopoietic Stem Cell Transplantation / adverse effects
-
Herpesvirus 4, Human / immunology*
-
Humans
-
Male
-
Premedication / methods*
-
Survival Rate
-
T-Lymphocytes, Cytotoxic / transplantation
-
T-Lymphocytes, Cytotoxic / virology
-
Treatment Outcome